After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

In February 2025, Novartis agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront payment of $925m. "Novartis to strengthen renal disease ...

The announcement comes less than three months after Novartis revealed that it would be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for approximately $3.1bn. The ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis has a collaboration agreement with ... The company acquired Anthos Therapeutics, a clinical-stage biopharmaceutical company, to broaden its cardiovascular portfolio.

Novartis is set to buy U.S. biotech Regulus Therapeutics for up to $1.7 billion in a move to boost its renal-disease pipeline. The Swiss pharma giant said Wednesday that it would pay Regulus ...